IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty
Wang, G; Wei, JR; Guan, YF; Jin, N; Mao, JM; Wang, X
刊名METABOLISM-CLINICAL AND EXPERIMENTAL
2005-05-01
DOI10.1016/j.metabol.2004.11.017
54期:5页:590-597
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Endocrinology & Metabolism
研究领域[WOS]Endocrinology & Metabolism
关键词[WOS]MONOCYTE CHEMOATTRACTANT PROTEIN-1 ; C-REACTIVE PROTEIN ; HUMAN ENDOTHELIAL-CELLS ; PPAR-GAMMA ; IN-VITRO ; GENE-EXPRESSION ; UNSTABLE ANGINA ; ATHEROSCLEROSIS ; TROGLITAZONE ; ATHEROGENESIS
英文摘要

Rosiglitazone, an agonist of peroxisome proliferator- activated receptor-gamma (PPAR gamma), is an insulin-sensitizing antidiabetic agent and inhibits restenosis in animal blood vessels. However, its benefit for patients with type 2 diabetes and coronary artery disease (CAD) after percutaneous coronary intervention is unknown. Patients with diabetes and CAD who had undergone percutaneous coronary intervention were randomized to either receive or not receive rosiglitazone,(4 mg/d) for 6 months. After 6 months of rosiglitazone treatment, the plasma levels of fasting glucose and insulin and those of hemoglobin A I C and homeostasis model assessment of insulin resistance were significantly decreased in the rosiglitazone group as compared with baseline levels and those in the control group. After 2 and 6 months of rosiglitazone treatment, the plasma level of high-density lipoprotein was significantly increased in the rosiglitazone group. In addition, plasma levels of monocyte chemoattractant protein-1 and C-reactive protein and hyperresponsiveness of low-dose lipopolysaccharide-induced monocyte chemoattractant protein-1 secretion from monocytes were reduced. Furthermore, the occurrence of coronary events was significantly decreased in the rosiglitazone group at 6-month follow-up. Our data indicate that rosiglitazone may protect the vascular wall through not only improving the features of metabolic disorders but also reducing proinflammatory responses and the occurrence of coronary events in patients with diabetes and CAD after percutancous coronary intervention. (c) 2005 Elsevier Inc. All rights reserved.

语种英语
WOS记录号WOS:000229205100006
引用统计
被引频次:47[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53977
专题北京大学第三临床医学院
作者单位1.Peking Univ, Dept Physiol, Beijing 100083, Peoples R China
2.Peking Univ, Ins Vasc Med, Third Hosp, Beijing 100083, Peoples R China
3.Peking Univ, Key Lab Mol Cardiovasc Sci, Educ Minist, Hlth Sci Ctr, Beijing 100083, Peoples R China
推荐引用方式
GB/T 7714
Wang, G,Wei, JR,Guan, YF,et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty[J]. METABOLISM-CLINICAL AND EXPERIMENTAL,2005,54(5):590-597.
APA Wang, G,Wei, JR,Guan, YF,Jin, N,Mao, JM,&Wang, X.(2005).Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.METABOLISM-CLINICAL AND EXPERIMENTAL,54(5),590-597.
MLA Wang, G,et al."Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty".METABOLISM-CLINICAL AND EXPERIMENTAL 54.5(2005):590-597.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, G]的文章
[Wei, JR]的文章
[Guan, YF]的文章
百度学术
百度学术中相似的文章
[Wang, G]的文章
[Wei, JR]的文章
[Guan, YF]的文章
必应学术
必应学术中相似的文章
[Wang, G]的文章
[Wei, JR]的文章
[Guan, YF]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。